• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纯合子家族性高胆固醇血症中低密度脂蛋白受体活性、低密度脂蛋白胆固醇水平与临床病程的关联

The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.

作者信息

Sprecher D L, Hoeg J M, Schaefer E J, Zech L A, Gregg R E, Lakatos E, Brewer H B

出版信息

Metabolism. 1985 Mar;34(3):294-9. doi: 10.1016/0026-0495(85)90015-0.

DOI:10.1016/0026-0495(85)90015-0
PMID:3856094
Abstract

Patients with homozygous familial hypercholesterolemia (FH), reveal a marked heterogeneity in plasma cholesterol levels, response to diet as well as drug treatment, and clinical course. Low-density lipoprotein (LDL) receptor activities were assessed by the rate of 14C-oleate cholesteryl ester biosynthesis in fibroblasts from 13 FH homozygotes in tissue culture. The receptor activity of the individual patients was highly correlated with initial pretreatment plasma cholesterol and LDL cholesterol levels (P less than .001, r = -0.89). In addition, the LDL receptor activity was positively correlated with the age of onset of angina based on the Cox model (P less than .035, likelihood ratio = 6.71). An association was also noted between LDL receptor activity and cholesterol reduction with drugs. These data provide direct evidence for the correlation between the heterogeneity of the LDL receptor and the expression of the clinical manifestations of homozygous FH. The determination of pretreatment plasma cholesterol level and LDL receptor activity in patients with homozygous FH provide useful parameters on which to base predictions of the clinical progression of cardiovascular disease. These parameters may also influence the selection of a program for diet and drug therapy. Patients with markedly elevated plasma cholesterol levels and very low LDL receptor activity should be considered to be candidates for multiple drug therapy, and portacaval shunt, and/or periodic plasma exchanges.

摘要

纯合子家族性高胆固醇血症(FH)患者在血浆胆固醇水平、对饮食及药物治疗的反应以及临床病程方面存在显著异质性。通过在组织培养中对13例FH纯合子成纤维细胞中14C -油酸胆固醇酯生物合成速率来评估低密度脂蛋白(LDL)受体活性。个体患者的受体活性与初始治疗前血浆胆固醇和LDL胆固醇水平高度相关(P <.001,r = -0.89)。此外,基于Cox模型,LDL受体活性与心绞痛发病年龄呈正相关(P <.035,似然比 = 6.71)。还注意到LDL受体活性与药物降胆固醇之间存在关联。这些数据为LDL受体异质性与纯合子FH临床表现表达之间的相关性提供了直接证据。测定纯合子FH患者治疗前血浆胆固醇水平和LDL受体活性可为预测心血管疾病临床进展提供有用参数。这些参数也可能影响饮食和药物治疗方案的选择。血浆胆固醇水平显著升高且LDL受体活性极低的患者应被视为多重药物治疗、门腔分流术和/或定期血浆置换的候选者。

相似文献

1
The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.纯合子家族性高胆固醇血症中低密度脂蛋白受体活性、低密度脂蛋白胆固醇水平与临床病程的关联
Metabolism. 1985 Mar;34(3):294-9. doi: 10.1016/0026-0495(85)90015-0.
2
Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia.一名纯合子家族性高胆固醇血症患者门腔分流术后胆固醇及低密度脂蛋白合成减少。
J Clin Invest. 1975 Dec;56(6):1420-30. doi: 10.1172/JCI108223.
3
A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.消胆胺与普罗布考治疗家族性高胆固醇血症的比较。
Atherosclerosis. 1984 Oct;53(1):1-7. doi: 10.1016/0021-9150(84)90099-6.
4
Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia.家族性缺陷载脂蛋白B与异质性家族性高胆固醇血症中载脂蛋白B代谢的比较。
Atherosclerosis. 2002 May;162(1):33-43. doi: 10.1016/s0021-9150(01)00679-7.
5
Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.阿托伐他汀治疗后多基因高胆固醇血症、家族性混合性高脂血症和家族性高胆固醇血症患者超离心分离的血浆脂蛋白亚组分的变化。
J Clin Lipidol. 2015 Mar-Apr;9(2):210-6. doi: 10.1016/j.jacl.2014.12.007. Epub 2014 Dec 16.
6
Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Am J Cardiol. 1986 Apr 15;57(11):933-9. doi: 10.1016/0002-9149(86)90733-2.
7
Stimulation of cholesteryl ester synthesis in mouse peritoneal macrophages by cholesterol-rich very low density lipoproteins from the Watanabe heritable hyperlipidemic rabbit, an animal model of familial hypercholesterolemia.来自渡边遗传性高脂血症兔(一种家族性高胆固醇血症动物模型)的富含胆固醇的极低密度脂蛋白对小鼠腹腔巨噬细胞中胆固醇酯合成的刺激作用。
J Clin Invest. 1986 May;77(5):1460-5. doi: 10.1172/JCI112458.
8
Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.纯合子家族性高胆固醇血症中的脂蛋白Lp(a):密度分布、颗粒异质性和载脂蛋白(a)表型。
Atherosclerosis. 1991 Jan;86(1):69-83. doi: 10.1016/0021-9150(91)90100-h.
9
Homozygous familial hypercholesterolemic patients in China.中国的纯合子家族性高胆固醇血症患者。
Atherosclerosis. 1985 Nov;57(2-3):303-12. doi: 10.1016/0021-9150(85)90042-5.
10
Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.儿童杂合子家族性高胆固醇血症:低密度脂蛋白受体突变分析及血浆脂蛋白-脂质浓度表达的变化
Atherosclerosis. 1996 Sep 27;126(1):163-71. doi: 10.1016/0021-9150(96)05907-2.

引用本文的文献

1
Functional characterization of variants in cell-based assays to investigate variant pathogenicity.基于细胞的检测中变异体的功能特征分析,以研究变异体的致病性。
Philos Trans R Soc Lond B Biol Sci. 2024 Apr 8;379(1899):20220377. doi: 10.1098/rstb.2022.0377. Epub 2024 Feb 19.
2
A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.靶向 LDL 受体依赖性和非依赖性通路治疗高胆固醇血症的研究进展述评,高胆固醇血症是 ASCVD 的主要危险因素之一。
Cells. 2023 Jun 16;12(12):1648. doi: 10.3390/cells12121648.
3
Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series.
载脂蛋白、脂质、低密度脂蛋白受体活性与接受 LDL 吸附治疗的激素抵抗型肾病综合征患者的临床病程:病例系列研究。
Intern Med. 2024 Feb 1;63(3):433-438. doi: 10.2169/internalmedicine.1922-23. Epub 2023 May 31.
4
In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in explain only part of LDL variability in an FH family.在一个 FH 家族中寻找 LDLc 变异性的遗传解释:常见 SNP 和一个罕见突变仅能解释 FH 家族中 LDL 变异性的一部分。
J Lipid Res. 2019 Oct;60(10):1733-1740. doi: 10.1194/jlr.M092049. Epub 2019 Aug 6.
5
Single step PCR for the identification of Low Density Lipoprotein Receptor (LDL-R) gene mutations.一步法 PCR 用于鉴定低密度脂蛋白受体 (LDL-R) 基因突变。
Pak J Med Sci. 2014 Jul;30(4):830-3. doi: 10.12669/pjms.304.4711.
6
Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia.一例纯合子家族性高胆固醇血症患者在4.5年后发生致命性心肌梗死。
JIMD Rep. 2012;2:45-50. doi: 10.1007/8904_2011_45. Epub 2011 Sep 6.
7
Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia.腺相关病毒血清型 8 基因治疗可显著降低杂合子和纯合子家族性高胆固醇血症人源化小鼠模型的血浆胆固醇水平。
Hum Gene Ther. 2013 Jan;24(1):19-26. doi: 10.1089/hum.2012.108. Epub 2012 Nov 14.
8
Statins in children: what do we know and what do we need to do?儿童使用他汀类药物:我们了解什么以及我们需要做什么?
Curr Atheroscler Rep. 2001 Jan;3(1):29-34. doi: 10.1007/s11883-001-0007-x.
9
Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.家族性高胆固醇血症复合杂合子对药物和饮食的反应
Arch Dis Child. 1995 Dec;73(6):538-40. doi: 10.1136/adc.73.6.538.
10
Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange.接受血浆置换治疗的纯合子家族性高胆固醇血症患者生存率提高。
Br Med J (Clin Res Ed). 1985 Dec 14;291(6510):1671-3. doi: 10.1136/bmj.291.6510.1671.